Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
- PMID: 15220038
- PMCID: PMC7112500
- DOI: 10.1016/S0140-6736(04)16506-9
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
Abstract
SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3.3 logs (95% CI 2.6-4.0 logs; p<0.001), completely prevented the development of SARS coronavirus-induced macroscopic lung pathology (p=0.013), and abolished shedding of virus in pharyngeal secretions. The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection.
Figures


Comment in
-
Mucosal immunisation and immunoprophylaxis as potential strategies for prevention of SARS.Lancet. 2004 Jun 26;363(9427):2102-3. doi: 10.1016/S0140-6736(04)16535-5. Lancet. 2004. PMID: 15220029 Free PMC article. No abstract available.
References
-
- Guan Y, Zheng BJ, He YQ. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 2003;302:276–278. - PubMed
-
- Parnes C, Guillermin J, Habersang R. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484–489. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous